<DOC>
	<DOCNO>NCT00025662</DOCNO>
	<brief_summary>This study evaluate safety effectiveness stem cell transplantation donor T lymphocytes undergone `` selective depletion . '' Certain patient cancer blood undergo transplantation donate stem cell generate new normally function bone marrow . In addition produce new bone marrow , donor 's T-lymphocytes also fight tumor cell might remain body . This attack tumor cell call `` graft-versus-leukemia '' ( GVL ) effect . However , another type T-lymphocyte donor may cause call `` graft-versus-host-disease '' ( GVHD ) , donor cell recognize patient 's cell foreign mount immune response reject . Selective depletion technique develop remove T-lymphocytes cause harmful GVHD , keep produce desirable GVL effect .</brief_summary>
	<brief_title>Selective T-Cell Depletion Reduce GVHD ( Patients ) Receiving Stem Cell Tx Treat Leukemia , Lymphoma MDS</brief_title>
	<detailed_description>Despite improved prophylaxis treatment , graft-versus-host disease ( GVHD ) remain major complication allogeneic stem cell transplantation . Although effective way prevent GVHD T cell depletion , process result poor immune function lead increase rate relapse , graft rejection , post-transplant infection . Ideally , method remove GVHD- produce effector cell retain broad T cell repertoire , include preservation 3rd party , antiviral anti-tumor response would desirable . Preclinical study lab demonstrate alloreactive T cell selectively remove donor lymphocyte pool vitro use specific immunotoxin direct interleukin-2 receptor . To test clinically , perform nonmyeloablative allogeneic stem cell transplant old patient hematologic malignancy . Although patient cured approach , significant morbidity mortality GVHD . At institution , nonmyeloablative transplantation associate incidence grade II-IV acute GVHD approximately 50 % . Although well tolerate young patient , patient age 50 year transplant-related mortality ( TRM ) approximately 35 % , mostly related GVHD . Through selective depletion alloreactive donor lymphocyte , hope reduce GVHD mortality , preserve transplant efficacy . Patients receive reduce intensity preparative regimen , follow mobilized peripheral blood stem cell allograft HLA-identical sibling donor , contain `` selectively-depleted '' donor lymphocytes . To obtain graft , colony stimulate factor ( G-CSF ) -mobilized peripheral blood donor undergoes positive cluster differentiation ( CD34 ) selection follow negative T cell selection use `` Nexell '' Isolex 300i system . This stem cell-rich , T cell-depleted product contain CD34+ cell dose least 5x10 ( 6 ) /kg . The unabsorbed fraction , remain positive CD34 selection , co-cultured 72 hour irradiate lymphocytes patient . The immunotoxin , RFT5-SMPT-dgA , add last 24 hour culture remove alloreacting cell . The washed T cell product ( CD3+ cell dose 1-4 x 10 ( 8 ) /kg ) cryopreserved . Following preparative regimen , patient receives successive infusion stem cell product select lymphocyte . All patient receive standard post transplant immunosuppression cyclosporine minimum 30 day , follow dose reduction depend degree donor lymphocyte chimerism . The primary end point study incidence severity acute GVHD . We also examine incidence chronic GVHD , engraftment , degree donor-host chimerism , transplant relate morbidity mortality , well disease-free overall survival . Stopping rule minimize risk untoward unexpected side effect .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>INCLUSION CRITERIA : PATIENT Ages 5075 year Relapsed CML chronic accelerate phase therapy STI571 ( Gleevec ) Acute lymphoblastic leukemia ( ALL ) , patient complete partial remission . Exceptions : T cell ALL Acute myelogenous leukemia ( AML ) : AML first complete partial remission include AML secondary chemotherapy prior hematological disease myelodysplastic syndrome , myeloproliferative disorder . Myelodysplastic syndrome : ( 1 ) refractory anemia excess blast ( RAEB ) , ( 2 ) refractory anemia excess blast transformation ( RAEBT ) , ( 3 ) MDS poor risk cytogenetics define complex karyotype ( great equal three anomaly ) chromosome 7 abnormality , ( 4 ) secondary MDS prior cytotoxic radiation therapy , ( 5 ) chronic myelomonocytic leukemia ( CMML ) Chronic lymphocytic leukemia ( CLL ) prolymphocytic leukemia , refractory nucleoside analog therapy , either progressive bulky disease anemia ( le 10 g/dl ) thrombocytopenia ( le 100,000/microliter ) due recent chemotherapy Mantle cell lymphoma Relapsed intermediate highgrade nonHodgkin 's lymphoma : ( 1 ) post autologous marrow PBSC transplant , ( 2 ) chemorefractory relapse . Exceptions : T cell NHL Relapse Hodgkin 's disease : ( 1 ) post autologous marrow PBSC transplant , ( 2 ) chemorefractory relapse Lowgrade follicular small lymphocytic lymphoma : ( 1 ) relapse follow conventional chemotherapy , ( 2 ) relapse follow autologous marrow PBSC transplant , ( 3 ) chemoresistant disease Life expectancy great 3 month Ability comprehend investigational nature study provide inform consent Availability HLAidentical family donor , 18 75 year old INCLUSION CRITERIA : DONOR HLA identical family donor , 18 75 year old Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke , history severe heart disease ) Ability comprehend investigational nature study provide inform consent EXCLUSION CRITERIA : RECIPIENT Pregnant lactate Eastern Cooperative Oncology Group ( ECOG ) performance status 3 Major anticipated illness organ failure incompatible survival PBSC transplant Diffusion Capacity fir carbon monoxide ( DLCO ) less 60 % predict Left ventricular ejection fraction le 40 % , angina . Absolute lymphocyte count le 300/mm ( 3 ) Serum creatinine great 2.5 mg/dl Serum bilirubin great 4 mg/dl , transaminases great 5x upper limit normal HIV positive Other malignant disease liable relapse progress within 2 year EXCLUSION CRITERIA : DONOR Pregnant lactate HIV positive . Donors positive Hepatitis B Virus , Hepatitis C Virus human tcell lymphoma virus ( HTLV ) use discretion investigator appropriate consent recipient Donor unfit receive GCSF undergo apheresis ( uncontrolled hypertension , history heart failure unstable angina , platelet count le 90,000/cu mm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Peripheral Blood Stem Cell</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Non-Myeloablative</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Chronic Myeloid Leukemia ( CML )</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Myelodysplasia ( MDS )</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Bone Marrow Transplant</keyword>
</DOC>